News | February 20, 2009

AMI Says Prepare for Changes in PET Coverage Under NOPR

February 20, 2009 - The Academy of Molecular Imaging recommends that PET imaging facilities closely monitor NOPR communications and be prepared for coverage changes on the date the final coverage decision is issued.

On January 6, 2009, CMS proposed significant changes to current coverage regarding Medicare's coverage of PET imaging under NOPR (see http://). Under the proposal, Medicare will provide coverage on a routine basis for many of the indications now reimbursed under NOPR. However, other indications would be covered only under a successor Coverage with Evidence Development (CED) program which likely will be somewhat different than the current NOPR program.

Medicare will publish its final coverage statement on or before April 6, 2009. The new policy becomes effective on the day it is published. The NOPR believes it should be possible to have a successor CED program in place when the NCD is published. However, until the day the new NCD is published, we will not know the details of the final coverage policy, whether any new codes or modifiers must be used for claims, nor whether a successor NOPR program has been cleared by CMS.

Although the new coverage policy will be effective on the day it is published, Medicare Contractors are allowed at least 30 days to implement required changes in their claims processing software, and in
their local coverage policies.

Each site should closely monitor NOPR communications, and be prepared for coverage changes on the date the final coverage decision is issued. In the past, when major coverage or fee schedule changes occurred, some providers have held claims until their contractors have implemented the new edits. As soon as additional information becomes available, we will make it available to participating PET facilities via these e-mail announcements and the NOPR website.

For more information: www.ami-imaging.org and www3.cms.hhs.gov/mcd/viewdraftdecisionmemo.asp?id=218

Related Content

Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a

While subject No. 1 (left) was judged as positive for both the neuronal injury and the amyloid load biomarker, both Alzheimer's disease biomarkers were negative in subject No. 2 (right). Image courtesy of Henryk Barthel et al., University Hospital Leipzig, Leipzig, Germany

News | PET Imaging | June 14, 2017
More people die of Alzheimer's disease than prostate and breast cancer combined. Identifying the disease before major...
News | Clinical Study | June 09, 2017
The milestone Imaging Dementia — Evidence for Amyloid Scanning (IDEAS) Study is working with government and academic...
Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers | May 22, 2017
May 22, 2017 — Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced t
low-dose lung CT scan

An example of a low-dose CT scan of the lungs, showing lung cancer. Image courtesy of Toshiba.

Feature | Lung Cancer | May 05, 2017 | Alison Grimes
The term mesothelioma was coined in 1909, just a few years after the introduction of medical X-ray imaging.
Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers | April 28, 2017
April 28, 2017 — Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the devel
Sponsored Content | Videos | Nuclear Imaging | April 28, 2017
David Wolinsky, M.D., director of nuclear cardiology at Cleveland Clinic Florida and past-president of the American S
News | Prostate Cancer | April 24, 2017
April 24, 2017 — Cancer Targeted Technology recently announced it is focusing on small molecules that target pivotal
PET
Feature | Imaging | April 11, 2017 | By Greg Freiherr
Positron emission tomography (PET) and other brain assessments
FDG-PET, cell mutations, lung cancer patients, non-small cell lung cancer, NSCLC, Journal of Nuclear Medicine study

From left to right are patients with EGFR mutation, KRAS mutation, and EGFR– and KRAS– tumors, respectively. Stage I and III tumors are shown in the top and bottom rows, respectively. Arrows indicate the locations of the lung tumors. Credit: Stephen S.F. Yip, Ph.D., and Hugo Aerts, Ph.D., Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Boston; John Kim, M.D., University of Michigan Health System, Ann Arbor, Mich.

News | PET Imaging | April 05, 2017
Researchers have used positron emission tomography (PET) to successfully identify genetic cell mutations that can cause...
Overlay Init